-
2
-
-
80055026968
-
Surgical treatment of uterine sarcoma
-
Nam JH. Surgical treatment of uterine sarcoma. Best Pract Res Clin Obstet Gynaecol. 2011;25:751-760.
-
(2011)
Best Pract Res Clin Obstet Gynaecol
, vol.25
, pp. 751-760
-
-
Nam, J.H.1
-
4
-
-
0020416825
-
Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma
-
Evans HL. Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma. Cancer. 1982;50:2170-2182.
-
(1982)
Cancer.
, vol.50
, pp. 2170-2182
-
-
Evans, H.L.1
-
5
-
-
54949157193
-
Prognostic factors and treatment outcomes of patients with uterine sarcoma: Analysis of 127 patients at a single institution, 1989-2007
-
Park JY, Kim DY, Suh DS, et al. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007. J Cancer Res Clin Oncol. 2008;134:1277-1287.
-
J Cancer Res Clin Oncol.
, vol.2008
, Issue.134
, pp. 1277-1287
-
-
Park, J.Y.1
Kim, D.Y.2
Suh, D.S.3
-
6
-
-
83055188443
-
The impact of tumor morcellation during surgery on the outcomes of patients with apparently early low-grade endometrial stromal sarcoma of the uterus
-
Park JY, Kim DY, Kim JH, et al. The impact of tumor morcellation during surgery on the outcomes of patients with apparently early low-grade endometrial stromal sarcoma of the uterus. Ann Surg Oncol. 2011;18:3453-3461.
-
(2011)
Ann Surg Oncol
, vol.18
, pp. 3453-3461
-
-
Park, J.Y.1
Kim, D.Y.2
Kim, J.H.3
-
9
-
-
15744376982
-
Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): Potential basis for a new therapeutic approach
-
Moinfar F, Gogg-Kamerer M, Sommersacher A, et al. Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): potential basis for a new therapeutic approach. Am J Surg Pathol. 2005;29:485-489.
-
(2005)
Am J Surg Pathol
, vol.29
, pp. 485-489
-
-
Moinfar, F.1
Gogg-Kamerer, M.2
Sommersacher, A.3
-
10
-
-
79955481960
-
Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy
-
Cheng X, Yang G, Schmeler KM, et al. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol. 2011;121:323-327.
-
(2011)
Gynecol Oncol.
, vol.121
, pp. 323-327
-
-
Cheng, X.1
Yang, G.2
Schmeler, K.M.3
-
11
-
-
9944259988
-
Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression
-
Geller MA, Argenta P, Bradley W, et al. Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression. Gynecol Oncol. 2004;95:632-636.
-
(2004)
Gynecol Oncol.
, vol.95
, pp. 632-636
-
-
Geller, M.A.1
Argenta, P.2
Bradley, W.3
-
12
-
-
33846900919
-
PDGFR-alpha as a potential therapeutic target in uterine sarcomas
-
Adams SF, Hickson JA, Hutto JY, et al. PDGFR-alpha as a potential therapeutic target in uterine sarcomas. Gynecol Oncol. 2007;104:524-528.
-
(2007)
Gynecol Oncol
, vol.104
, pp. 524-528
-
-
Adams, S.F.1
Hickson, J.A.2
Hutto, J.Y.3
-
13
-
-
33750299476
-
PDGF-alpha and PDGF-beta are expressed in endometrial stromal sarcoma: A potential therapeutic target for tyrosine kinase inhibitors?
-
Liegl B, Reich O, Nogales FF, et al. PDGF-alpha and PDGF-beta are expressed in endometrial stromal sarcoma: a potential therapeutic target for tyrosine kinase inhibitors? Histopathology. 2006;49:545-546.
-
(2006)
Histopathology
, vol.49
, pp. 545-546
-
-
Liegl, B.1
Reich, O.2
Nogales, F.F.3
-
15
-
-
44349166828
-
KIT protein expression in uterine sarcomas: An immunohistochemical study and review of the literature
-
Zafrakas M, Theodoridis TD, Zepiridis L, et al. KIT protein expression in uterine sarcomas: an immunohistochemical study and review of the literature. Eur J Gynaecol Oncol. 2008;29:264-266.
-
(2008)
Eur J Gynaecol Oncol
, vol.29
, pp. 264-266
-
-
Zafrakas, M.1
Theodoridis, T.D.2
Zepiridis, L.3
-
16
-
-
0037378396
-
Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary
-
Klein WM, Kurman RJ. Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary. Int J Gynecol Pathol. 2003;22:181-184.
-
(2003)
Int J Gynecol Pathol
, vol.22
, pp. 181-184
-
-
Klein, W.M.1
Kurman, R.J.2
-
17
-
-
16544371910
-
Prevalence of KIT expression in human tumors
-
Went PT, Dirnhofer S, Bundi M, et al. Prevalence of KIT expression in human tumors. J Clin Oncol. 2004;22:4514-4522.
-
(2004)
J Clin Oncol.
, vol.22
, pp. 4514-4522
-
-
Went, P.T.1
Dirnhofer, S.2
Bundi, M.3
-
18
-
-
1242318769
-
Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: A case series
-
Leath CA 3rd, Straughn JM Jr, Conner MG, et al. Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series. J Reprod Med. 2004;49:71-75.
-
(2004)
J Reprod Med
, vol.49
, pp. 71-75
-
-
Leath Iii, C.A.1
Straughn Jr., J.M.2
Conner, M.G.3
-
20
-
-
0141757485
-
Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT
-
Rushing RS, Shajahan S, Chendil D, et al. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT. Gynecol Oncol. 2003;91:9-14.
-
(2003)
Gynecol Oncol
, vol.91
, pp. 9-14
-
-
Rushing, R.S.1
Shajahan, S.2
Chendil, D.3
-
21
-
-
33847320613
-
Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations
-
Liegl B, Gully C, Reich O, et al. Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations. Histopathology. 2007;50:448-452.
-
(2007)
Histopathology
, vol.50
, pp. 448-452
-
-
Liegl, B.1
Gully, C.2
Reich, O.3
-
22
-
-
84857672358
-
Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro
-
Bilir A, Erguven M, Ermis E, et al. Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro. J Gynecol Oncol. 2011;22:225-232.
-
(2011)
J Gynecol Oncol.
, vol.22
, pp. 225-232
-
-
Bilir, A.1
Erguven, M.2
Ermis, E.3
-
23
-
-
58249127460
-
Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma
-
Kalender ME, Sevinc A, Yilmaz M, et al. Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma. Cancer Chemother Pharmacol. 2009;63:555-559.
-
(2009)
Cancer Chemother Pharmacol
, vol.63
, pp. 555-559
-
-
Kalender, M.E.1
Sevinc, A.2
Yilmaz, M.3
-
24
-
-
33846208614
-
KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate
-
Mitsuhashi T, Nakayama M, Sakurai S, et al. KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate. Ann Diagn Pathol. 2007;11:49-54.
-
(2007)
Ann Diagn Pathol
, vol.11
, pp. 49-54
-
-
Mitsuhashi, T.1
Nakayama, M.2
Sakurai, S.3
-
25
-
-
33646739922
-
A case of c-kit positive high-grade stromal endometrial sarcoma responding to imatinib mesylate
-
Salvatierra A, Tarrats A, Gomez C, et al. A case of c-kit positive high-grade stromal endometrial sarcoma responding to imatinib mesylate. Gynecol Oncol. 2006;101:545-547.
-
(2006)
Gynecol Oncol.
, vol.101
, pp. 545-547
-
-
Salvatierra, A.1
Tarrats, A.2
Gomez, C.3
|